Premium
Myocardial Na,K‐ATPase and Digoxin Therapy in Human Heart Failure
Author(s) -
KJELDSEN KELD,
BUNDGAARD HENNING
Publication year - 2003
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2003.tb07285.x
Subject(s) - digoxin , digitalis , heart failure , atpase , medicine , cardiology , ejection fraction , digitalis glycosides , endogeny , chemistry , endocrinology , biochemistry , enzyme
A bstract : The specific binding of digitalis glycosides to the Na,K‐ATPase is used as a tool for Na,K‐ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K‐ATPase concentration is decreased, and the decrease in Na,K‐ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis‐like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality‐reducing therapy.